Benchling, a San Francisco, CA-based life sciences R&D cloud platform, closed $50m in Series D funding.
The round was led by Alkeon with participation from new investors Spark Capital, Lux Capital and ICONIQ Partners, as well as existing investors Thrive Capital, Benchmark and Menlo Ventures.
The company intends to use the funds to build advanced product capabilities, expand its international presence, and drive adoption across leading R&D organizations.
Led by Saji Wickramasekara, CEO and founder, Benchling provides an R&D cloud platform powering the life science industry. It offers unified R&D solutions purpose-built for biotech, including Notebook, Molecular Biology, Registry, Inventory, Request & Workflow Management, and Insights. The solution is used globally across the largest multinational pharmaceutical corporations, emerging biotechnology companies, and renowned research institutions. Since launching in 2012, more than 230,000 scientists and 1,000 R&D organizations have adopted it to centralize complex experimental datasets and optimize R&D processes.